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Recent characterization of the human elastin gene 
identified three putative glucocorticoid responsive el-
elIlents (GRE) within the 5'-flanking DNA. To test the 
functionality of these cis-elelIlents, transgenic lIlice 
that express a human elastin prolIloter-reporter gene 
( CAT) construct in a tissue-specific lIlanner were in-
jected with triamcinolone acetonide (TMC) or dexa-
lIlethasone (DEX), two glucocorticosteroids in clinical 
use. Subcutaneous injection of these glucocorticoids 
resulted in a lIlarked, up to 28-fold, enhancement of 
the CAT activity in the skin at the site of injection. 
Elastin is a major component of elastic fibers that provide elasticity and resilience to tissues, including the arterial blood vessels, the lungs, and the skin (for reviews see [1-3]). The initially synthesized elastin polypeptide, 70 kDa in size, is encoded by a 3.5-kb mRNA. The human 
elastin gene, which resides on chromosome 7 [4], consists of 34 
exons within a gene spanning approximately 45 kb of genomic 
DNA [5] . 
Regulation of elastin gene expression has been demonstrated to 
take place at several different levels. For example, interleukin-l{3 [6] 
and insulin-like growth factor-I [7] have been shown to enhance 
elastin gene expression at the transcriptional level, whereas 1,25-di-
hydroxy vitamin D3 has been suggested to down-regulate elastin 
gene expression at the post-transcriptional level by destabilizing the 
mRNA [8] . In addition, the initially transcribed pre-mRNA under-
goes extensive alternative splicing that results in the synthesis of 
polypeptides with slightly differing primary sequences [9,10] . 
We have recently cloned the entire human elastin gene, includ-
ing 5.2 kb of the 5' -flanking DNA, and we have sequenced 2.6 kb of 
the promoter region [5,11]. The nucleotide sequences at the pro-
moter region of the elastin gene have revealed several interesting 
features, including the lack of a canonical TATA sequence, which 
may explain the presence of multiple transcription initiation sites 
[5]. In addition to multiple SP-l and AP-2 binding sites, we also 
identified several additional putative regulatory cis-elements [11]. 
These include three putative glucocorticoid responsive elements 
(GRE), TGTTC [12], at positions -[1,437 to 1,433], -[1,315 to 
1,311], and -[1,023 to 1,019] (counting upstream from the transla-
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SilIlilarly, intraperitoneal injection of DE X resulted in 
significant increases in the elastin promoter activity in 
various internal organs. Furthermore, incubation of 
skin fibroblast and aortic smooth muscle cell cultures 
established from the transgenic animals with TMC (10 
ng/IIlI) resulted in marked increases in the elastin pro-
moter activity. These studies delIlonstrate that gluco-
corticosteroids act as powerful up-regulators of human 
elastin promoter activity in transgenic mice. ] Invest 
DermatoI103:632-636, 1994 
tion initiation site). Previous studies utilizing animal and cell cul-
ture models for elastin gene expression have suggested that these 
glucocorticoid responsive elements may be functional in the elastin 
gene [13 - 16]. Specifically, glucocorticoids have been shown to 
stimulate elastin synthesis in chick embryo aortae [13,14,16] and in 
differentiated bovine fetal ligamentum nuchae fibroblasts in culture 
[15], as determined at the protein and mRNA levels. However, the 
reported increases have been relatively modest. For example, in one 
study, treatment with 10-8 M DEX increased elastin synthesis by 
only two- to threefold in differentiated cell cultures, whereas DEX 
caused no induction of elastin synthesis in undifferentiated cells 
from early gestation animals [15] . Furthermore, another study [16] 
revealed that hydrocortisone stimulated elastin synthesis in 14-d 
chick embryo aortae, whereas no effect was noted in the 7-day -old 
chicks and a significant inhibition of elastin synthesis was observed 
in 14-day-old chick aortae. Consequently, these results suggested 
that the effects of hydrocortisone on the synthesis of aortic elastin is 
modulated by the developmental stage of the animal [16] . Never-
theless, based on these observations, it is conceivable that the effects 
of glucocorticosteroids may be mediated through binding of lig-
and-receptor complexes to putative glucocorticoid responsive ele-
ments in the elastin promoter region [12]. 
To further examine the effects of glucocorticosteroids on elastin 
gene expression, in this study we have utilized transgenic mice that 
express the human elastin promoter-reporter (CAT) gene construct 
in a tissue- and development-specific manner [17] . This construct 
contains 5' -flanking DNA of the human elastin gene spanning from 
-5,200 to +2, and therefore contains the three putative glucocorti-
coid responsive elements (see above). Subcutaneous injection of the 
transgenic mice with triamcinolone acetonide (TMC) or DEX, or 
incubation of fibroblast and smooth muscle cell cultures established 
from the skin and aortae of these animals, respectively, with the 
same glucocorticosteroids, resu lted in a marked increase in the elas-
tin promoter activity. Furthermore, intraperitoneal il~ection of 
DEX resulted in similar increases in elastin promoter activity in 
internal organs. 
/ 
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MATERIALS AND METHODS 
Transgenic Mice The development of a transgenic mouse line expressing 
the human elastin promoter/CAT construct is described elsewhere [17]. 
The animals were injected either subcutaneously or intraperitoneally with 
TMC (Kenalog-l0, E.R. Squibb and SOilS, Princeton, NJ) or DEX (dexa-
methasone sodium phosphate, American Regent Laboratories, Shirley, NY) 
in concentrations indicated in Results. The glucocorticosteroids were diluted 
in 200 J.lI saline, and the control animals received an equal volume of saline. 
At different time points, the animals were sacrificed and skin biopsies were 
performed at the ~ite of t~e sub~utaneo~s injection, and variouso~ga?s were 
obtained from ammals 1I1Jected lntrapentoneally. The CAT activIty 111 these 
tissues was determined as described below. 
Cell Cultures Fibroblast cultures were established from the skin of the 
transgenic animals by explanting tissue specimens onto the tissue culture 
plastic and allowing cells to migrate to the surrounding area. The primary 
culrures were maintained in Dulbecco's modified Eagle's medium supple-
mented with 5% fetal bovine serum, 5% newborn bovine serum, 2 mM 
glutamine, and antibiotics. Smooth mus~le cell cultures were similarly es-
tablished from aortae of the transgeruc ammals, and the cultures were ma1l1-
tained in M-199 medium containing the same supplements as above. The 
primary cell cultures were passaged by trypsinization, and the subcultures in 
passages 2 or 3 were incubated with TMC or DEX in varying concentrations 
for the time periods indicated ill Results. At the end of the incubations, CAT 
activity was determined in the cells. as described below. 
CAT Assay To determine the expression of the human elastin promoter 
in the transgenic animals ill .,ivo and in cell cultures established from these 
animals, CAT activity as a reporter of the promoter activity was determined. 
For extraction of the CAT from the tissues, the specimens were homoge-
nized in 0.25 M Tris-HCI, pH 7.5, using a Polytron tissue homogenizer. 
The homogenates were centrifuged at 10,000 Xg for 15 min at +4"C. and 
the protein concentration in the supernatant was determined by a commer-
cial protein assay kit (BioRad). 
Aliquots of the supernatant containing protein in amounts specified in the 
figure legends (usually 100 J.lg) were then used for assay of the CAT activity 
by incubation with p4CJchioramphenicoi as substrate, as described else-
where [17-20]. 
RESULTS 
Upregulation of Human Elastin Promoter Activity by Glu-
co corticosteroids in the Skin of Transgenic Mice To test the 
effects of glucocorticosteroids on the transcriptional activity of the 
human elastin promoter, 5-day-old transgenic mice were injected 
subcutaneously with 10 or 100 ng ofTMC. After 24 h, CAT activ-
ity was determined from the treated skin. The results indicated that 
a single injection with as little as 10 ng ofTMC resulted in a sixfold 
increase in the promoter activity, whereas injection of 100 ng of 
TMC increased the activity by 28-fold (Fig 1). II~ection of 100 ng 
of DEX resulted in a 6 .6-fold increase in CAT activity, whereas 1 Ilg 
resulted in a 21.3-fold increase (Table I). 
To examine the time-course of the enhancement of CAT activity 
by TMC, biopsy specimens were obtained from different homozy-
gous littermates, which initially demonstrated the same level of 
CAT activity, at time points vatying from 0 to 72 h after a single 
injection of 100 ng ofTMC. The results indicated that the relative 
CAT activity was significantly increased already at 6 h following 
the injection, and maximum levels of enhancement were achieved 
at 12-24 h. Thereafter, a decline in the activity was noted, but the 
values at 72 h were sti ll 4 .6-fold higher than those in the control 
skin (Fig 2). 
To examine if organs other than the skin might also respond to 
glucocorticosteroids by increasing the elastin promoter activity, 
two sets of transgenic mice (2 weeks and 6 months of age) were 
injected intraperitoneally with DEX, in doses of 0.8 and 1.6 mg/kg 
of body weight, diluted in a total volume of200,u1. Six hours later, 
several organs, which have previously been shown to express the 
human elastin promoter in a tissue specific manner [17] , were dis-
sected, and CAT activity was determined. In control animals receiv-
ing 200 III of saline, the highest CAT activity was noted in the 
lungs, whereas lower levels of activity were noted in the heart, 
kidney, and skin (Table II). DEX increased the elastin promoter 
activity in the lungs and the kidneys up to 15.1- and 8.7-fold, 
respectively (Fig 3 and Table II). Similarly, up to 11.9- and 8.7-
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Figure 1. Up-regulation of human elastin promoter activity in the 
skin of transgenic mice injected subcutaneously with TMC. Five-
day - old transgenic mice expressing the human elastin promoter-CAT con-
struct were injected subcutaneously with TMC using the amounts indicated. 
Twenty-four hours later. punch biopsy specimens of the skin were obtained 
from the site of injection, and CAT activity was determined using 100 Ilg of 
protein extract in a 16-h incubation with [14C]chloramphenicol, as described 
in Materials and MetHods . The figure is an autoradiogram illustrating the 
separation of acetylated (AC) and non-acetylated (C) forms of radioactive 
chloramphenicol ' by thin-layer chromatography. The controls (CTL) in-
cluded an extract of lung of a homozygous untreated animal as a positive 
control (+), and the negative control (-) consisted of the substrate incubated 
with an extract from a non-transgenic wild-type mouse. The CAT activity 
was quantitated by counting the radioactivity in acetylated and non-acety-
lated forms of p<C]chloramphenicol and expressed as percent of acetylation, 
as shown. The relative activity in animals receiving 10 Or 100 ng TMC was 
calculated in relation to control animals. which received saline alone (1.00). 
Each lane represents an assay from a separate animal within a litter of homo-
zygous transgenic animals. 
fo ld increases were noted in the heart and the skin (Table II). It 
should be noted that both concentrations (0.8 and 1.6 mg/kg) gave 
essentially the same responses, indicating maximal effect already 
with the lower concentrations. However, a difference was noted in 
that the older (6-month - old) animals were less responsive to DEX 
than the younger (2-week-old) mice (Table II). 
Glucocorticosteroids Upregulate Human Elastin Promoter 
Activity In Vitro To test the effects of the same glucocorticoster-
oids on the elastin promoter activity in cell cultures, dermal fibro-
blasts derived from the skin of the transgenic mice were incubated 
with varying concentrations ofTMC. These cells, which were ex-
amined in passage 2 or 3, retain their capacity to express the human 
elastin promoter, as determined by CAT activity [6]. Incubation of 
these cells with TMC in concentrations vatying from a to 10 ng/ml 
for 24 h resulted in a dose-dependent increase in the CAT activity, 
and the relative activity in cultures incubated with 10 ng/ml of 
TMC showed up to a 73-fold increase, as compared to control 
cultures incubated in parallel without TMC (Fig 4). Similar incu-
bations were performed with DEX and these assays also demon-
strated a dose-dependent enhancement of the human elastin pro-
moter activity (Table I). Again, however, higher concentrations of 
DEX were needed to achieve a similar degree of up-regulation and, 
specifically, cells incubated in the presence of 1 ng/ml of DEX 
showed only about 4.3-fold increase in the CAT activity, whereas 
10 ng/ml yielded a 42.7-fold enhancement (Table I). Thus, the 
cell-culture experiments suggest that the dermal fibroblast is a tar-
get cell for glucocorticoid action in the skin of the transgenic mice, 
and that efficient enhancement of the elastin promoter activity can 
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Table I. Effects of DE X on Human Elastin Promoter 
Activity in Transgenic Mice and Skin Fibroblast Cultures· 
DEX Dose Test System CAT Activityb Fold Enhancementb 
Experiment 1 
2.3 1.0 Controls Mouse 
100 ng Mouse 15.6 6.6 
1000 ng Mouse 50.3 21.3 
Experiment 2 
Controls Mouse 1.0 1.0 
100 ng Mouse 2.1 2.1 
1000 ng Mouse 21.3 21.3 
Experiment 3 
Fibroblast 0.4 1.0 Controls 
1 ng/ml Fibroblast 1.9 4.3 
10 ng/ml Fibroblast 18.5 42.6 
Experiment 4 
Fibroblast 0.5 1.0 Controls 
1 ng/ml Fibroblast 0.8 1.8 
10 ug/ml Fibroblast 5.6 11.9 
• Transgenic mice expressing the human elastin promoter-CAT reponer gene con-
struct were injected subcutaneously with a single dose of dexametasone, and CAT 
activity was determined in the skin 24 h later (experiments 1 and 2). Fibroblast cultures 
established from the skin of the transgenic animals were incubated in the presence of 
dexamethasone in concentrations indicated for 24 h (experiments 3 and 4), and CAT 
activity was assayed as shown in Fig 1. 
I CAT activity is expressed as percent of acetylation of [14C]chloramphenicol used as 
substrate, when 100 Jlg of protein extract either from the skin or fibroblast cultures were 
incubated for 16 h, as described in Materials a .. d Metlaods. The fold enhancement of CAT 
activity in the presence of dexamethasone is expressed in relation to parallel controls 
(1 .0) within each experiment. The values are means of two or three determinations, 
each assayed in duplicate. 
be achieved under in vitro conditions in the absence of other cell 
types. . . 
To examine if other cell types, which are actively synthesizing 
elastin, would also be responsive to glucocorticosteroids, smooth 
muscle cell cultures were established from the aortae of the trans-
genic animals and incubated with 10 ngj ml ofTMC. Assay of CAT 
activity after 24 h of incubation indicated a 22.S-fold increase in the 
promoter activity (average from two separate experiments, each 
assay performed in duplicate) (Fig 5). 
DISCUSSION 
Collectively, the data of this study indicate that glucocorticoster-
oids clearly enhance elastin gene expression at the promoter level. 
The enhancement of the promoter activity is probably mediated by 
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Figure 2. Time course of the effect of TMC on elastin promoter 
activity in the skin. Transgenic animals received a single subcutaneous 
injection ofTMC (100 ng), and CAT activity was determined at the time 
points indicated, as described in Materials and Methods and in Fig 1. The 
values represent the mean ± the range of individual values noted in three 
separate experiments, each time point consisting of two individual animals. 
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Table II. Human Elastin Promoter Activity in the 
Internal Organs of Transgenic Mice Following 
Intraperitoneal Injection ofDEX· 
DEXb DEXb 
Controlb (0.8 mg/kg) (1.6 mg/kg) 
Experiment 1 
Lungs 3.2 (1.0) 48.5 (15.1) 47.8 (14.9) 
Heart 3.0 (1.0) 35.6 (11.9) 35.2 (11.7) 
Kidney 0.4 (1.0) 2.6 (6.5) 3.5 (8.7) 
Skin 1.6 (1.0) 12.8 (8.0) 13.9 (8.7) 
Experiment 2 
Lungs 3.8 (1.0) 29.8 (7.8) 38.8 (10.2) 
Heart 1.4 (1.0) 1.6 (1.1) 3.5 (2.5) 
Kidney 1.4 (1.0) 7.0 (5 .0) 11.7 (8.3) 
II Transgenic mice, either 2 weeks of age in cxpcritncnt t. or 6 months of age in 
experiment 2, were injected intraperitoneally with DEX, either 0.8 or 1.6 mg/kg. Six 
hours later, the organs were dissected and CAT activity was determined as described in 
Materials a .. d Methods and in Fig 1. The CAT activity was determined by incubation of 
15 Jlg of protein in the supernatant of each tissue extract, except the lungs and the 
kidney in experiment 1, in which cases 7.5 Jlg of protein was used. 
• The values are expressed as percent acetylation of the radioactive chloramphenicol 
in a 3-h incubation. The values in parentheses represent the fold enhancement of CAT 
activity noted in DEX-treated animals in comparison with controls (1.0) receiving 
saline injection alone. 
the putative glucocorticoid responsive elements (GRE) previously 
identified in the human elastin promoter region [11]. It should be 
noted, however, that the three putative glucocorticoid responsive 
elements identified in the human elastin promoter region do not 
entirely conform with the proposed consensus sequence for GRE, 
GGTACAnnnTGTTCT [12] . In fact, all three sequences identified 
in the elastin gene promoter depict the sequence TGTTCC, which 
has homology with the downstream half-site of the consensus GRE, 
whereas the upstream sequences have lower degrees of homology 
[1] . However, experimental evidence with other mammalian genes 
has suggested that the proposed consensus sequence for GRE may 
not be universal [21,22] . 
The glucocorticosteroids tested in this study have a wide variety 
of effects on various cellular functions, including several previously 
demonstrated effects on connective tissue metabolism [23]. For ex-
ample, glucocorticosteroids have been shown to suppress the syn-
thesis of collagen by fibrob lasts, and some studies have indicated 
that glucocorticosteroids increase collagenase activity, although 
other reports have also suggested inhibitory effects on collagenase 
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Figure 3. Effects of an intraperitoneal injection of DEX on CAT 
activity in the kidney and the lungs. Six-month -old transgenic mice 
received a single peritoneal injection of DEX, either 0 (-), 0.8 (+), or 1.6 
(++) mg/kg. The animals were sacrificed 6 h later and CAT activity was 
determined by incubating 7.5 )1g of protein extract from the kidneys or the 
lungs for 3 h with radioactive chloramphenicol as substrate. 
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Figure 4. Demonstration of enhanced elastin promoter activity in 
fibroblast cultures established from the skin of transgenic mice. Cell 
CUltures were incubated in serum-free medium with TMC in the concentra-
tions indicated. After 24 h of incubation, CAT activity was detemlined in 
the cells using 100 J.l.g of protein in a 16-h incubation with ["CJchloram-
~henicol as substrate. The CAT activity was expressed as percent of acetyla-
tIOn, as described in Fig 1. The positive (+) and negative (-) controls (CTL) 
were the same as in Fig 1. The relative activity in fibroblast cultures incu-
bated with varying concentrations of TMC was calculated in relation to 
cOntrol cultures incubated in parallel without the glucocorticoid (1.00) . 
Each lane represents determination from an individual cell culture. 
activity [23,24). Nevertheless, these observations suggest that glu-
cocorticosteroids are predominantly anti-anabolic with respect to 
collagen metabolism in tissues. 
In the present study, we clearly demonstrate up-regulation of 
human elastin gene expression at the promoter level, and this effect 
is noted in both relatively young (5 d to 2 weeks post-natal) and 
older (6 months) transgenic animals. It should be noted that the 
enhancement of elastin-promoter activity by TMC is less pro-
nounced in the older mice than in younger animals, but no inhibi-
tion of the promoter activity is observed in our studies in the dosage 
range of the glucocorticosteroid used . The latter finding contrasts 
with the conclusions of Keeley and Johnson (16) who, after intra-
peritoneal injection of hydrocortisone (100 jJ.g/g chick weight), 
noted a small, 30 percent, decrease in the synthesis of insoluble 
aortic elastin in 14-day-old chicks, wheras similar treatment of 1-
day-old chicks resulted in a modest, 45 percent, increase in the 
synthesis of insol uble elastin. Again, these differences may reflect 
the use of different experimental system or could reflect post-tran-
scriptional and translational effects of the glucocorticosteroids on 
elastin synthesis . 
Previously, glucocorticosteroids have been shown to decrease the 
activity of elastase released from cultured macrophages, and the 
inhibition was suggested to be mediated by corticosteroid receptors 
[24,25). Also, an elastase-like neutral protease, which has been 
found in human skin fibroblast cultures, has been shown to be 
inhibited by DEX (23). Thus, glucocorticosteroids, in addition to 
enhancing elastin gene expression, may also inhibit degradation of 
extracellular elastic fibers by e1astases, a group of proteolytic en-
zymes secreted by inflammatory and fibroblastic cells. Conse-
quently, the net effect of glucocorticosteroid treatment on elastin 
would be increased accumulation of this protein in tissues. 
It is of interest to note that in our experimental system, TMC is 
consistently about a to-times more powerful up-regulator of elastin 
gene expression than DEX when the same concentrations of these 
two steroids are tested in parallel. This difference could be explained 
by differential tissue availability of these glucocorticosteroid prepa-
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Figure 5. Demonstration of enhanced elastin promoter activity in 
smooth muscle cell cultures established from the aortae of trans-
genic mice. The cells were incubated without or with TMC (10 ngjml) for 
24 h, and CAT activity was then determined with 15 J.l.g of protein in a 3-h 
incubation. 
rations, TMC being a suspension of particles whereas DEX is a 
solution. This observation suggests the possibility that the trans-
genic mouse line used in this study may provide a biologic in vivo 
model to test the relative pharmacologic potency of various gluco-
corticosteroid preparations, using a GRE-containing promoter (the 
human elastin gene) as a target for Iigand-receptor- mediated ac-
tion. 
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ANNOUNCEMENT 
The European Society of Dermatological Research Clinically Oriented Symposium, "Vitamin 
D: Actions and Applications in Dermatology" will be held April 27-29,1995 in Aarhus, 
Denmark. 
The international symposium is intended to bring together investigators interested in both 
basic science and clinical medicine. The program will include invited speakers for introductory 
lectures as well as free communications (oral and poster presentations) . Selected papers from the 
symposium will be published in the Journal oj Investigative Dermatology . 
. The progra.m w~ll include the biology of vitamin D; expression, regulation, and gene regula-
tion of the vltamll1 D receptor; photobiology of Vitamin D, role of cytokines and growth 
factors; immunomodulatory role (lymphocytes, macrophages, Langerhans cells); cell differen-
tiation and photobiology; clinical experience with vitamin D analogs; clinical tolerability and 
safety; and potential use in lymphomas and carcinomas. 
The organizing secretariat includes Knud Kragballe (Denmark), Thomas Krieg (Germany), 
Karsten Fogh (Denmark), Christian Gr011h0j Larsen (Denmark), John J. Voorhees (USA), 
Jean-Hilaire Saurat (Switzerland), Daniel Bikle (USA), Peter van de Kerkhof (The Nether-
lands), Michael Holick (USA), and Klaus Bendtsen (Denmark). 
For information contact Knud Kragballe, MD, PhD, Department of Dermatology, Marselis-
borg Hospital, DK-8000 Aarhus C, Denmark. Tel. +45 89 49 18 56; Fax +45 89 49 18 70. 
